Introduction {#section5-1947603515580983}
============

Osteochondral lesions are caused by trauma, osteochondritis dissecans (OCD), or osteonecrosis. Current treatment options include minced bone and cartilage paste,^[@bibr1-1947603515580983]^ mosaicplasty,^[@bibr2-1947603515580983]^ allogeneic osteochondral transplantation,^[@bibr3-1947603515580983][@bibr4-1947603515580983]-[@bibr5-1947603515580983]^ combined bone and chondrocyte transplantation, the so-called sandwich technique, and synthetic osteochondral implants.^[@bibr6-1947603515580983][@bibr7-1947603515580983]-[@bibr8-1947603515580983]^ These treatment methods suffer from inconsistent clinical and biological outcome, high cost, and donor site morbidity. The limitations of the existing treatment methods call for new osteochondral treatment strategies to be developed and validated. A potential strategy is to use autologous or allogeneic cartilage chips. Chondrocytes from human cartilage chips embedded in fibrin glue has been shown to migrate from the cartilage chips and form extracellular matrix^[@bibr9-1947603515580983],[@bibr10-1947603515580983]^ and in 1983, Albrecht *et al.*^[@bibr11-1947603515580983]^ implanted minced autologous cartilage chips in osteochondral defects in rabbits and reported complete closure of the defects with hyaline cartilage. In recent years, clinical studies on cartilage chips have been emerging. Full-thickness chondral injuries have been treated successfully by Farr *et al*.^[@bibr12-1947603515580983],[@bibr13-1947603515580983]^ and Buckwalter *et al*.^[@bibr14-1947603515580983]^ using allogeneic particulated juvenile articular cartilage (PJAC), and by Cole *et al*.^[@bibr15-1947603515580983],[@bibr16-1947603515580983]^ using autologous cartilage chips embedded in a biodegradable scaffold (Cartilage Autograt Implantation System, CAIS). These techniques are for full-thickness chondral defects, and until now, autologous cartilage chips have not been used to treat osteochondral defects clinically.

In this study, we present the preliminary findings on autologous dual-tissue transplantation (ADTT) for osteochondral repair. ADTT is a combination of fragmented autologous bone press-fitted into the bed of the defect, and autologous cartilage chips embedded in fibrin glue to cover the bone graft. The aim of the study was to evaluate the early biological repair potential of ADTT using magnetic resonance imaging (MRI), computed tomography (CT), and clinical outcome scores. We hypothesized that ADTT-treated patients would display improved clinical outcome and good biological healing 1 year postoperative.

Materials and Methods {#section6-1947603515580983}
=====================

Patients {#section7-1947603515580983}
--------

Patients suffering from focal osteochondral defects in the knee were included in the study. Inclusion criteria were the following: symptomatic focal osteochondral lesions, age 18 to 55 years, patient agreement to follow rehabilitation protocol, and patient agreement to attend follow-up visits. Exclusion criteria were the following: advanced osteoarthritis defined as grade 2 or higher Tönnis score,^[@bibr17-1947603515580983]^ untreated meniscal lesion, untreated ruptures of the cruciate ligaments, untreated ruptures of collateral ligaments, malalignment \>5°, poor general health ASA (American Society of Anesthesiologists) 3 or higher, alcohol or drug abuse, systemic or intra-articular corticoid steroid treatment within the past 6 months, or diagnosed malignancy. The patient demographics are listed in [**Table 1**](#table1-1947603515580983){ref-type="table"}.

###### 

Patient Demographics and Defect Details.

  Characteristics                                   Values
  ------------------------------------------------- -----------------
  Age, years, mean ± SD                             32 ± 7
  Sex, male:female                                  5:3
  Injury etiology                                   
   Osteochondritis dissecans                        8
  Defect location                                   
   Medial femoral condyle                           6
   Lateral femoral condyle                          1
   Trochlea                                         1
  Defect size after debridement, cm^2^, \[range\]   3.1 \[1.5-4.7\]
  Defect depth after debridement, mm, \[range\]     8.4 \[6-12\]

Surgery {#section8-1947603515580983}
-------

Prior to the open-surgery procedure, a knee arthroscopy was performed to identify the defect and additional joint pathology. Following the arthroscopy, the defect was exposed through a parapatellar arthrotomy. Using a hollow trephine, the defect was debrided to a point where the bottom of the defect consisted of healthy trabecular bone (clinical visual assessment), and the edges of the defect, of healthy articular cartilage. The defect size after debridement is described in [**Table 1**](#table1-1947603515580983){ref-type="table"}. A biopsy of cancellous autologous bone was harvested through a drill hole in the proximal tibia and digitally broken down into fragments. The bone fragments were press-fitted into the bone part of the defect, to a level approximately 2 mm beneath the surface of the cartilage. Fibrin glue was applied to seal the bony part of the defect. For every square centimeter of defect being repaired, approximately 250 mg of hyaline cartilage was harvested. The biopsy was taken from the nonweightbearing femoral trochlea. Using surgical scissors, the cartilage was chipped to a size of approximately 0.25 to 0.5 mm^2^. The cartilage chips were dispersed throughout the defect, either touching or in very close proximity to each other (Within 0.5-1 mm). Fibrin glue was added and allowed to set for 5 minutes. To ensure proper placement of the cartilage chip--fibrin glue plug, the knee was continuously flexed and extended. The steps of the surgery are presented in [**Figure 1a-d**](#fig1-1947603515580983){ref-type="fig"}.

![Autologous dual-tissue transplantation in 4 steps. (**a**) The defect has been debrided, so stable shoulders of healthy articular cartilage remain. The bottom of the defect consists of healthy subchondral bone. (**b**) A bone biopsy is taken from the proximal tibia. (**c**) The fragmented bone is press fitted into the defect. (**d**) The autologous cartilage chips, embedded in fibrin glue, are transplanted into the defect.](10.1177_1947603515580983-fig1){#fig1-1947603515580983}

Postoperative Rehabilitation {#section9-1947603515580983}
----------------------------

All patients attended a stepwise activity progression program for the first 3 months postoperative. The patients were allowed 0° to 30° range of motion for the first 2 weeks in a hinged brace. From 2 weeks and onward, full range of motion was allowed. No weightbearing was allowed from 0 to 2 weeks. From 2 to 6 weeks, partial weightbearing was allowed. Impact activities were allowed after 6 months. Trained physiotherapists supervised the postoperative rehabilitation. Nonsteroidal anti-inflammatory drugs were prohibited for the initial 3 months.

Clinical Evaluation {#section10-1947603515580983}
-------------------

The clinical outcome was evaluated using the International Knee Documentation Committee Subjective Knee Form (IKDC), the Knee injury and Osteoarthritis Outcome Score (KOOS), and the Tegner score.^[@bibr18-1947603515580983][@bibr19-1947603515580983]-[@bibr20-1947603515580983]^ A qualified medical professional performed evaluation via telephone preoperative and 1 year postoperative.

Magnetic Resonance Imaging {#section11-1947603515580983}
--------------------------

For evaluation of osteochondral repair, patients were scanned prior to surgery and 1 year postoperative. The images were evaluated by an experienced blinded radiologist using the 3-dimensional (3D) MOCART (magnetic resonance observation of cartilage repair tissue) score.^[@bibr21-1947603515580983]^ The images were evaluated according to defect fill, cartilage interface, bone interface, repair tissue surface, repair tissue structure, signal intensity, subchondral lamina, chondral osteophytes, bone marrow edema, subchondral bone, and joint effusion. The maximal achievable score was 100.

Magnetic resonance imaging on all patients was performed using an ONI Optima 430s 1.5T extremity scanner (GE Healthcare, Buckinghamshire, UK). Following sequences were acquired for evaluation: Axial STIR, coronal FSE T1, sagittal SmartFat-fat water separation technique (FSEfw) PD FS, sagittal water FSEfw PD FS, and sagittal 3D T2\* mapping.

Computed Tomography {#section12-1947603515580983}
-------------------

For subchondral bone evaluation, patients underwent CT scans 1 year postoperative. A Philips Brilliance 40 scanner (Eindhoven, the Netherlands) was used with a slice thickness of 0.625 mm. An experienced blinded observer evaluated the CT images using Osirix (Geneva, Switzerland, v. 5.7, 64-bit). Bone regeneration in the osteochondral defects was evaluated semiquantitatively according to the degree bone formation in the defect: ≤20%, 21% to 40%, 41% to 60%, 62% to 80% or \>80%.

Statistical Analysis {#section13-1947603515580983}
--------------------

The data from the MOCART, KOOS, IKDC, and Tegner scores were tested for normality using histograms and Q-Q plots, and for equality of variance using SD-tests. Paired Student *t* tests were performed on normally distributed data, while nonparametric data were analyzed using Wilcoxon rank sum test. Statistical analysis was performed using STATA/MP version 13.0 (StataCorp, College Station, TX, USA).

Results {#section14-1947603515580983}
=======

No postoperative complications were seen in any patients. One patient was unavailable for clinical scoring

Clinical Scores {#section15-1947603515580983}
---------------

The individual clinical scores for each patient combined with the corresponding MRI and CT image is presented in [**Table 2**](#table2-1947603515580983){ref-type="table"}. A statistical significant improvement from preoperative to 1 year postoperative was seen in the IKDC score, the KOOS pain, KOOS symptoms, KOOS sport/recreation, KOOS quality of life, and the Tegner score. KOOS activities of daily living did not improve significantly. The mean scores are listed in [**Table 3**](#table3-1947603515580983){ref-type="table"}.

###### 

The Individual Clinical Scores and the Corresponding Figure Number.

  Score                         Pt 1   Pt 2    Pt 3^[a](#table-fn2-1947603515580983){ref-type="table-fn"}^   Pt 4             Pt 5   Pt 6    Pt 7   Pt 8                                                                        
  ----------------------------- ------ ------- ------------------------------------------------------------- ---------------- ------ ------- ------ ----------------------- ------ ------- ------ ------- ------ ------- ------ -------
  IKDC                          57.5   71.3    37.9                                                          86.2             ---    ---     36.8   36.8                    10.3   60.9    10.3   71.3    37.5   75.9    60.9   74.4
  KOOS                                                                                                                                                                                                                          
   Pain                         83     97      56                                                            97               ---    ---     58     58                      25     72      31     83      75     92      81     92
   Symptoms                     82     86      54                                                            86               ---    ---     64     58                      32     79      57     93      61     89      68     93
   ADL                          81     82      81                                                            96               ---    ---     24     76                      24     76      26     84      93     100     94     99
   Sport/recreation             40     60      30                                                            95               ---    ---     0      25                      0      25      5      35      5      65      40     65
   QOL                          31     69      19                                                            75               ---    ---     44     64                      6      56      6      63      19     50      44     63
  Tegner                        6      9       1                                                             3                ---    ---     3      3                       1      3       1      5       1      4       3      4
  Corresponding figure number   1a     1b, c   1d                                                            1e, f            1g     1h, i   1j     1k, l                   2a     2b, c   2d     2e, f   2g     2h, i   2j     2k, l
  Previous surgery              None   None    Drilling                                                      Trufit OC plug   None   None    None   MaioRegen OC scaffold                                                       

ADL = activities of daily living; IKDC = International Knee Documentation Committee; KOOS = Knee injury and Osteoarthritis Outcome Score; OC = osteochondral; PreOP = preoperative; Pt = patient; QOL = quality of life.

Patient number 3 was unavailable for clinical scoring.

###### 

The IKDC, KOOS, Tegner, and MOCART Scores.

  Score               Preoperative   SD     1 year   SD     Difference   95% CI      *P*
  ------------------- -------------- ------ -------- ------ ------------ ----------- ---------
  IKDC                36.9           20     68.1     15.7   32.2         11.2-53.1   \<0.001
  KOOS                                                                               
   Pain               58.3           23.4   84.5     14.5   26.2         3.5-48.8    \<0.05
   Symptoms           63.3           17.3   83.3     12.1   20.1         2.6-37.5    \<0.05
   ADL                74.8           24.0   85.4     14.0   10.6         12.2-33.5   NS
   Sport/recreation   24.3           17.4   57.2     22.7   33.0         9.4-56.4    \<0.01
   QOL                27.7           13.9   62.7     8.1    35.0         21.8-48.3   \<0.01
  Tegner              2.6            1.8    4.7      2.2    2.1          0.9-3.4     \<0.01
  MOCART              22.5           8.5    52.5     14.4   30           17.3-42.7   \<0.001

ADL = activities of daily living; IKDC = International Knee Documentation Committee; KOOS = Knee injury and Osteoarthritis Outcome Score; MOCART = magnetic resonance observation of cartilage repair tissue; NS = not significant; QOL = quality of life; SD = standard deviation.

Magnetic Resonance Imaging {#section16-1947603515580983}
--------------------------

The MOCART score significantly improved at 1 year in terms of defect fill (*P* \< 0.01), cartilage interface (*P* \< 0.01), repair tissue surface (*P* \< 0.05), and repair tissue signal intensity (*P* \< 0.01). No significant improvement was found in the categories; bone interface, repair tissue structure, subchondral lamina, chondral osteophytes, subchondral edema, subchondral bone, and effusion (*P* \> 0.05). The total MOCART score improved from 22.5 to 52.5 at 1 year (*P* \< 0.01) ([**Table 3**](#table3-1947603515580983){ref-type="table"}). Preoperative and 1 year postoperative images of each patient can be found in [**Figures 2**](#fig2-1947603515580983){ref-type="fig"} and [**3**](#fig3-1947603515580983){ref-type="fig"}.

![Magnetic resonance imaging (MRI) and computed tomography (CT) of patients 1 to 4. First column (**a**, **d**, **g**, and **j**) is preoperative MRI. Second column (**b**, **e**, **h**, and **k**) is 1 year MRI. Third column (**c**, **f**, **i**, and **l**) is 1 year CT. Each row represents 1 patient. (**a**) An International Cartilage Repair Society (ICRS) grade IV osteochondritis dissecans (OCD). (**b**, **c**) A good repair tissue integration and complete bone filling.](10.1177_1947603515580983-fig2){#fig2-1947603515580983}

![Magnetic resonance imaging (MRI) and computed tomography (CT) of patients 5 to 8. First column (**a**, **d**, **g**, and **j**) is preoperative MRI. Second column (**b**, **e**, **h**, and **k**) is 1 year MRI. Third column (**c**, **f**, **i**, and **l**) is 1 year CT. Each row represents 1 patient. (**i**, **l**) Incomplete subchondral bone integration. (**l**) Bone fragments in the chondral repair tissue.](10.1177_1947603515580983-fig3){#fig3-1947603515580983}

Computed Tomography {#section17-1947603515580983}
-------------------

All patients had \>80% bone filling in the defects. The subchondral surface congruence of the repair tissue was very similar to the adjacent bone, but the surface seemed uneven in all 8 patients. Two patients had small bone fragments in the chondral repair tissue ([**Figs. 2l**](#fig2-1947603515580983){ref-type="fig"} and [**3l**](#fig3-1947603515580983){ref-type="fig"}) and 2 patients had incomplete subchondral bone integration ([**Fig. 3i**](#fig3-1947603515580983){ref-type="fig"} and [**l**](#fig3-1947603515580983){ref-type="fig"}).

Discussion {#section18-1947603515580983}
==========

This is the first clinical report on ADTT for OCD in the knee. The primary finding of this early report was a consistent, good biologic healing response of ADTT in osteochondral lesions. The biologic healing response was characterized by very good subchondral bone restoration and the cartilage repair was characterized by good cartilage interface integration, defect filling, surface structure and near normal tissue signal intensity.

The use of cartilage chips for hyaline cartilage repair was introduced in 1983.^[@bibr11-1947603515580983]^ Chondrocytes from cartilage chips have been shown to migrate from the chips and form new extracellular matrix,^[@bibr9-1947603515580983],[@bibr10-1947603515580983]^ and it has been shown that chondrocytes are not significantly damaged when cartilage is cut using sharp instruments.^[@bibr22-1947603515580983]^ Since 1983, however, reports have been sparse and limited to *in vitro* and experimental studies, and studies on cartilage-bone paste.^[@bibr1-1947603515580983],[@bibr9-1947603515580983],[@bibr23-1947603515580983][@bibr24-1947603515580983][@bibr25-1947603515580983][@bibr26-1947603515580983]-[@bibr27-1947603515580983]^ Recently, studies on cartilage chips have been emerging, perhaps due to the need for a universally available, low-cost treatment for injuries in this troublesome tissue.^[@bibr12-1947603515580983],[@bibr13-1947603515580983],[@bibr15-1947603515580983],[@bibr16-1947603515580983]^ As in the present study PJAC (DeNovo NT Natural Tissue Graft, Zimmer Inc, Warsaw, IN, USA) and CAIS use cartilage chips. The main difference however is that ADTT treats osteochondral injuries rather than full-thickness chondral injuries. Furthermore, the PJAC treatment use 1 mm^3^ *allogeneic* cartilage chips embedded in fibrin glue, while CAIS use autologous chips of the same size, embedded in a biodegradable scaffold. Since data suggests that the increased surface achieved by reducing the size of the cartilage chips, increase the extracellular matrix production *in vitro*,^[@bibr28-1947603515580983]^ we used chips sized 0.25 to 0.5 mm^3^. To avoid the need to purchase a commercially available scaffold or membrane, we used autologous bone graft and cartilage, both readily available in the patient, and sealed the defect with fibrin glue. Since the chondrocytes from cartilage chips expand and create extracellular matrix, it is possible to treat large lesions without increasing the donor site morbidity.

The subchondral unit, consisting of the articular cartilage and the subchondral bone, is important to restore in any attempt to repair an osteochondral defect. Signals from the subchondral bone have been shown to alter the differentiation potential of bone marrow stem cells and thereby induce phenotypic degenerative changes toward osteoarthritis.^[@bibr29-1947603515580983]^ Furthermore, studies have indicated that osteoarthritis could be initiated through the activation of a secondary ossification center with thickening of the subchondral bone plate and thereby thinning of the articular cartilage.^[@bibr30-1947603515580983]^

To ensure reestablishment of the subchondral unit, several different treatment methods have been implemented. The impact on clinical outcome of these treatment methods is overall relatively similar. Gel-type autologous chondrocyte implantation is a 2-step procedure using autologous bone graft, a fibrin scaffold, and cultured chondrocytes. Using gel-type autologous chondrocyte implantation on 9 patients suffering from osteochondral injuries on either the lateral or medial femoral condyles, Könst *et al*.^[@bibr31-1947603515580983]^ found an increase in the IKDC score from 35 ± 16 preoperative to 57 ± 20 at 1 year (mean IKDC increase 22). In "mosaicplasty," osteochondral allografts are transplanted from low weightbearing parts of the knee to the osteochondral defect. It provides good results in active younger patients with isolated osteochondral lesions; however, donor site morbidity is a concern with this technique, limiting treatment to smaller defects.^[@bibr32-1947603515580983],[@bibr33-1947603515580983]^ Filardo *et al*.^[@bibr34-1947603515580983]^ treated 31 patients, suffering from osteochondral injuries in the medial or lateral femoral condyle, with mosaicplasty, and found an IKDC increase from 40 ± 16 to 63 ± 18 at 1 year (mean IKDC increase 23). The MaioRegen scaffold is a layered biomimetic scaffold designed to be implanted into osteochondral defects and induce subchondral bone, and cartilage regeneration. It has shown promising clinical results in osteochondral defects of up to 3 to 8 cm^2^ on the femoral condyles, trochlea, and tibial plateau; however, the biological repair potential of the scaffold has recently been questioned.^[@bibr35-1947603515580983]^ Authors have reported preoperative to 1 year IKDC increases from 36 ± 6 to 68 ± 13,^[@bibr36-1947603515580983]^ 45 ± 19 to 71 ± 18,^[@bibr37-1947603515580983]^ and 48 ± 18 to 76 ± 13^[@bibr38-1947603515580983]^ (mean IKDC increase 32, 26, and 28 respectively). In the present study, the ADTT treatment resulted in an IKDC increase from preoperative to 1 year of 36 ± 20 to 68 ± 15---a statistically and clinically significant increase of 32 points, which is similar to or better than previously published studies investigating methods for osteochondral repair.

Even though statistical significant clinical and radiological improvements were found in this study, 1 patient (patient 4) had a radiological improvement, but no clinical improvement, and 1 patient (patient 8) had a radiological deterioration, but a slight clinical improvement. Patient 4 had previously been treated with the Trufit osteochondral plug, and patient 8 had previously been treated with the MaioRegen osteochondral scaffold. Both scaffold treatments had failed and we speculate if failed treatment with osteochondral implants can impede future treatment attempts. An event observed in chondral defects after microfracture.^[@bibr39-1947603515580983],[@bibr40-1947603515580983]^ Furthermore, a variable subchondral bone healing was found in patients 7 and 8. While a biological variation, even when using autologous bone grafts are expected, a possible explanation for the failure of patient 8 is the previous use of the MaioRegen scaffold, which has been shown to impede subchondral bone healing.^[@bibr35-1947603515580983]^

This study is limited by the small sample size (n = 8), the short follow-up, and the lack of a control group. The risk of a type 1 error is present, but based on the small variance in data and the thorough clinical and radiological follow-up program showing improvements in subchondral bone and cartilage restoration, we conclude that these early results on ADTT are very encouraging. The fact that there is no need of a scaffold or cell culturing makes ADTT a promising, low-cost treatment method for osteochondral injuries.

Larger, controlled, long-term studies should be performed to validate this treatment principle.
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